The article discusses the genetic mechanisms underlying the development of neuropathies in myeloma - a tumor of bone marrow plasma cells. Although these mechanisms are not yet fully understood, research points to several potential factors, including mutations in myeloma cell lineage-associated genes such as the MMSET/NSD2 gene and transcription factors such as IRF4. Another important factor is the immune system disorder that accompanies myeloma and can lead to damage to nerve fibers. More detailed studies are required to fully understand the genetic mechanisms of the development of neuropathies in myeloma.

Genetic mechanisms, neuropathies, immune system

Palumbo, A., & Anderson, K. (2011). Multiple myeloma. New England Journal of Medicine, 364(11), 1046-1060.

Rajkumar, S. V., & Kumar, S. (2016). Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings, 91(1), 101-119.

Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2019). How to treat patients with relapsed/refractory multiple myeloma. Leukemia, 33(4), 1099-1112.

Cavo, M., Terpos, E., & Nanni, C. (2020). Role of imaging techniques in the management of multiple myeloma: a consensus statement from the International Myeloma Working Group. The Lancet Oncology, 21(8), e360-e376.

Usmani, S. Z., Heuck, C., & Mitchell, A. (2019). Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica, 104(5), e211-e214.

Sonneveld, P., Avet-Loiseau, H., & Lonial, S. (2016). Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 127(24), 2955-2962.